« Previous Next » The Journal of Urology
Volume 184, Issue 4 , Pages 1572-1573 , October 2010

Reply by Authors

References

Makarov DV, Humphreys EB, Mangold LA, et al. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. J Urol. 2006;176:554
Zhu H, Roehl KA, Antenor JA, et al. Biopsy of men with PSA level of 2.6 to 4.0 ng/ml associated with favorable pathologic features and PSA progression rate: a preliminary analysis. Urology. 2005;66:547
Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70
American Urological Association (AUA). Prostate-specific antigen (PSA) best practice policy. Oncology (Williston Park). 2000;14:267
- MEDLINE
Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2009;182:2232
Han M, Partin AW, Piantadosi S, et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 2001;166:416
Ramos J, Uchio E, Aslan M, et al. Changes in Gleason scores for prostate cancer: what should we expect from a measurement?. J Investig Med. 2010;58:625
Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007;69:1095